Clinical Trials Logo

Serum; Disease clinical trials

View clinical trials related to Serum; Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04426006 Completed - Sars-CoV2 Clinical Trials

Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic

PRO-SERO-COV
Start date: June 18, 2020
Phase: N/A
Study type: Interventional

The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.

NCT ID: NCT04152005 Completed - Serum; Disease Clinical Trials

Endothelin Concentrations in a Population With Cardiovascular Disease and Periodonitis

Start date: January 1, 2016
Phase:
Study type: Observational

Recently, a key role played in the ethiology of periodontitis has been highlighted by a Endothelin (ET-1). ET1 possess the ability to express surface antigens of endothelial and hematopoietic stem cells and to assist in maintaining vascular integrity and the repair mechanism of the endothelium. ET originate from bone marrow

NCT ID: NCT03180775 Not yet recruiting - Atherosclerosis Clinical Trials

Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Recently, the investigators have been screening for anti-atherogenic or pro-atherogenic amino acids (AAs) in the macrophage model system to better understand their role in atherogenesis. The findings so far suggest that specific AAs induce selective anti-atherogenic effects (glycine, alanine, leucine and cysteine) or pro-atherogenic effects (glutamate and glutamine) in macrophages. Taking together the above previous reports with the mechanisms behind macrophage foam cell formation and atherogenesis, it is possible that AAs could be anti-atherogenic or pro-atherogenic via their mechanism of action on macrophage foam cell formation. This paradigm may serve as a basis for the development of novel cardio-protective, anti-atherogenic nutritional, or therapeutic approaches, that should be studied in human trials.

NCT ID: NCT02894931 Recruiting - Atherosclerosis Clinical Trials

Effects of Dietary Interventions on Serum and Macrophage Atherogenicity

Start date: September 2016
Phase: N/A
Study type: Interventional

While previous atherosclerosis-related studies have focused mainly on the atherogenicity of lipids, the proposed study aims to investigate the effects of other dietary factors, i.e. monosaccharides, disaccharides, amino acids, or artificial sweeteners, on the atherogenicity of serum or macrophages. Findings from the current proposed study may shed light on yet unknown mechanisms by which the above dietary factors could affect atherosclerosis development and CVD risk and hence could possibly assist in the future development of anti-atherogenic strategies.